XORTX arranges $114,500 (U.S.) private placement

Mr. Allen Davidoff reports XORTX ANNOUNCES USD $114,500 PRIVATE PLACEMENT XORTX Therapeutics Inc. has arranged a non-brokered private placement to raise up to $114,500 (U.S.) through the issuance of up to 156,849 common share units of the company at a price of 73 U.S. cents per unit. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder, on exercise, to purchase one additional common share in the capital of the company, at a price of $1.20 (U.S.) per warrant until the close of business on the day, which is 60 months from the date of issuance of the units, provided, however, that, if the closing price of the common shares on Nasdaq is greater than $2 (U.S.) for 10 or more consecutive trading days, the warrants will be accelerated, and the warrants will expire on the 30th business day following the date of such notice. Allen Davidoff, chief executive officer of XORTX, stated, "With additional interest in the LIFE offering (see news release of June 26 and July 22, 2025) from non-Canadian investors, XORTX has undertaken this small private placement to accommodate these subscribers." The closing date of the offering is expected to occur on or about Aug. 5, 2025, or such later date or dates as the company may determine, and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals, including approval from the TSX Venture Exchange. The company intends to use the proceeds of the offering for gout programs and general corporate and working capital purposes. All securities issued under the offering will be subject to a four-month-and-one-day hold period under applicable Canadian securities legislation. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: (1) its lead XRx-026 program for the treatment of gout; (2) its XRx-008 program for ADPKD; and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, it is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. We seek Safe Harbor.